Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment.

Sever O. N., Oktay K., Güzel E., Kaya V., Güzel A., Yıldırım M.

Indian journal of cancer, cilt.58, ss.91-95, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 58
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4103/ijc.ijc_758_18
  • Dergi Adı: Indian journal of cancer
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.91-95
  • Anahtar Kelimeler: Glioblastoma, recurrence, reoperation, survival, PROGNOSTIC-FACTORS, REPEATED SURGERY, PHASE-III, BEVACIZUMAB, TRIAL, RADIOTHERAPY, TEMOZOLOMIDE, COMBINATION, MULTIFORME, LOMUSTINE
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: Treatment options for recurrent glioblastoma (GBM) have limited efficacy. Although reoperation is useful for both the confirmation of the diagnosis of recurring disease and the relief of the symptoms, its effect on survival is unknown. The aim of this study was to evaulate the impact of second surgery in recurrent GBM. Methods: Patients with GBM followed in our center between January 2015 and April 2018 were analyzed retrospectively based on the treatment options. Results: 25 patients diagnosed with recurrent GBM were analyzed. Ten patients (40%) were treated with chemotherapy following reoperation, and 15 patients (60%) were treated with only chemotherapy. No benefits of reoperation were observed in the univariate analysis. Conclusion: The second surgery in recurrent GBM has limited effect in clinical course.